Premium
No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy results from a randomized clinical trial of 303 patients
Author(s) -
Lebeau B.,
Chastang C.,
Muir J. F.,
Vincent J.,
Massin F.,
Fabre C.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930301)71:5<1741::aid-cncr2820710507>3.0.co;2-q
Subject(s) - medicine , aspirin , chemotherapy , lung cancer , randomized controlled trial , clinical trial , oncology , cancer , surgery
Background . Experimental, and more recently, clinical data have suggested the influence of hemostasis in the spread of malignant disease. Methods . To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy. Results . Survival was not increased in the aspirintreated group ( P = 0.90). The analysis according to the extent of disease (limited or extensive disease) did not modify that conclusion. Conclusions . This result does not confirm the hypothesis that, in SCLC, aspirin (a platelet aggregation inhibitor) reduces metastasis formation and local tumor thrombogenesis.